Codiak BioSciences, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 23 rows in 2022. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2022-06-17: Reporting owner Haddock Jason; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2022-06-17: Reporting owner Bernstein Karen; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2022-06-17: Reporting owner Eggimann Anne-Virginie; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2022-06-17: Reporting owner MELAS KYRIAZI THEO; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2022-06-17 | Haddock Jason Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $2.83 exercise price | 2022-06-21 | |
| 2022-06-17 | Bernstein Karen Director | 4 | Stock Option (Right to Buy) Derivative · Indirect · See footnote | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $2.83 exercise price | 2022-06-21 | |
| 2022-06-17 | Eggimann Anne-Virginie Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $2.83 exercise price | 2022-06-21 | |
| 2022-06-17 | MELAS KYRIAZI THEO Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $2.83 exercise price | 2022-06-21 | |
| 2022-06-17 | COONEY CHARLES L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $2.83 exercise price | 2022-06-21 | |
| 2022-06-17 | GILLIS STEVEN Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $2.83 exercise price | 2022-06-21 | |
| 2022-06-17 | Pandite Arundathy N. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $2.83 exercise price | 2022-06-21 | |
| 2022-05-04 holding as of filing | Mauro David J Officer (Chief Medical Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $12.70 exercise price | 2022-05-04 | ||
| 2022-05-02 | Mauro David J Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +200,000 200,000 owned after | $3.26 exercise price | 2022-05-04 | |
| 2022-02-16 | WILLIAMS DOUGLAS E Director, Officer (President & CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +61,250 61,250 owned after | $5.21 exercise price | 2022-02-18 | |
| 2022-02-16 | Brudnick Richard Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,850 10,850 owned after | $5.21 exercise price | 2022-02-18 | |
| 2022-02-16 | Bain Linda Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,300 20,300 owned after | $5.21 exercise price | 2022-02-18 | |
| 2022-02-16 | Howze Yalonda Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,950 12,950 owned after | $5.21 exercise price | 2022-02-18 | |
| 2022-02-16 | Sathyanarayanan Sriram Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +19,600 19,600 owned after | $5.21 exercise price | 2022-02-18 | |
| 2022-02-16 | Konstantinov Konstantin Officer (Chief Technology Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,200 11,200 owned after | $5.21 exercise price | 2022-02-18 | |
| 2022-02-16 | Barna Nicole Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,400 8,400 owned after | $5.21 exercise price | 2022-02-18 | |
| 2022-01-19 | Brudnick Richard Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +41,000 41,000 owned after | $7.21 exercise price | 2022-01-21 | |
| 2022-01-19 | Howze Yalonda Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +52,000 52,000 owned after | $7.21 exercise price | 2022-01-21 | |
| 2022-01-19 | WILLIAMS DOUGLAS E Officer (President & CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +200,000 200,000 owned after | $7.21 exercise price | 2022-01-21 | |
| 2022-01-19 | Barna Nicole Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +29,000 29,000 owned after | $7.21 exercise price | 2022-01-21 | |
| 2022-01-19 | Sathyanarayanan Sriram Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +45,000 45,000 owned after | $7.21 exercise price | 2022-01-21 | |
| 2022-01-19 | Konstantinov Konstantin Officer (Chief Technology Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +42,000 42,000 owned after | $7.21 exercise price | 2022-01-21 | |
| 2022-01-19 | Bain Linda Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +65,000 65,000 owned after | $7.21 exercise price | 2022-01-21 |